Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure
- PMID: 318933
- DOI: 10.1161/01.cir.55.2.375
Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure
Abstract
Dobutamine is a newly developed catecholamine reported to have minimal direct vascular effects relative to its inotropic activity and to have less chronotropic and arrhythmogenic properties than other catecholamines used in the treatment of low output states. In this study, the acute hemodynamic effects of dobutamine were compared to those of dopamine in 13 patients with chronic low output cardiac failure. At dosages adjusted to achieve similar increments in cardiac output, dobutamine reduced left ventricular filling pressure (LVEP) from 24 +/- 2 mm Hg (SEM) to 17+/- 2 mm Hg, while dopamine increased LVEP to 30 +/- 3 mm Hg and in six patients caused arterial O2 saturation to fall below 90%. This poor response to dopamine was probably the result of its vasoconstrictive effects and illustrates the potential advantages of using a cardioselective agent such as dobutamine when the desired goal of therapy is to improve ventricular function by direct inotropic stimulation.
Similar articles
-
[Dopamine and dobutamine in the treatment of severe cardiac failure (author's transl)].Dtsch Med Wochenschr. 1978 Dec 1;103(48):1915-21. doi: 10.1055/s-0028-1129367. Dtsch Med Wochenschr. 1978. PMID: 710319 Clinical Trial. German.
-
The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure.Circulation. 1977 Sep;56(3):468-72. doi: 10.1161/01.cir.56.3.468. Circulation. 1977. PMID: 884803
-
[Comparative study of the effects of dobutamine and dopamine in septic shock].Ann Anesthesiol Fr. 1978;19(10):859-62. Ann Anesthesiol Fr. 1978. PMID: 35059 Clinical Trial. French.
-
[Combination of dopamine and dobutamine in the differential therapy of acute and chronic myocardial failure].Dtsch Med Wochenschr. 1985 Apr 12;110(15):598-603. doi: 10.1055/s-2008-1068872. Dtsch Med Wochenschr. 1985. PMID: 2983969 Review. German. No abstract available.
-
Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.Prog Cardiovasc Dis. 1977 Jan-Feb;19(4):327-40. doi: 10.1016/0033-0620(77)90007-x. Prog Cardiovasc Dis. 1977. PMID: 12536 Review. No abstract available.
Cited by
-
Comparison of the cardiodynamic and metabolic effects of dobutamine with those of norepinephrine and dopamine in the dog isolated heart.Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):174-9. doi: 10.1007/BF00174866. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3185745
-
Bretylium and dobutamine in the treatment of coronary artery disease.Bull N Y Acad Med. 1979 Sep;55(8):798-809. Bull N Y Acad Med. 1979. PMID: 290401 Free PMC article. No abstract available.
-
Dopamine in cardiac failure and shock.Br Med J. 1977 Dec 17;2(6102):1563-4. Br Med J. 1977. PMID: 589346 Free PMC article. No abstract available.
-
Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril.Br Heart J. 1981 Nov;46(5):528-30. doi: 10.1136/hrt.46.5.528. Br Heart J. 1981. PMID: 7032556 Free PMC article.
-
Influence of dobutamine and dopamine on hemodynamics and plasma concentrations of noradrenaline and renin in patients with low cardiac output following acute myocardial infarction.Eur J Clin Pharmacol. 1980 Oct;18(3):213-7. doi: 10.1007/BF00563001. Eur J Clin Pharmacol. 1980. PMID: 7002564
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources